Clearside Biomedical, Inc. financial data

Symbol
CLSDQ on OTC
Location
Alpharetta, GA
Fiscal year end
31 December
Latest financial report
10-Q - Q3 2025 - 14 Nov 2025

Key Ratios

Label TTM Value / Value Unit Change %
Current Ratio 367 % -26.7%
Debt-to-equity -138 % +41.4%
Return On Equity 55.5 % -56.1%
Return On Assets -145 % -56%
Operating Margin -690 % -116%

Shares

Label TTM Value / Value Unit Change %
Entity Common Stock, Shares Outstanding 5.23M shares -93.1%
Common Stock, Shares, Outstanding 5.23M shares -93%
Entity Public Float 92M USD +43.8%
Common Stock, Value, Issued 78K USD +4%
Weighted Average Number of Shares Outstanding, Basic 5.23M shares +5.04%
Weighted Average Number of Shares Outstanding, Diluted 5.23M shares +5.04%

Income Statement

Label TTM Value / Value Unit Change %
Revenue from Contract with Customer, Excluding Assessed Tax 3.33M USD -56.8%
Research and Development Expense 13.2M USD -36%
General and Administrative Expense 12.7M USD +8.37%
Operating Income (Loss) -23M USD +6.84%
Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest -5.97M USD +22.3%
Income Tax Expense (Benefit) 0 USD
Net Income (Loss) Attributable to Parent -26M USD +18.5%
Earnings Per Share, Basic 0 USD/shares +26%
Earnings Per Share, Diluted 0 USD/shares +26%

Balance Sheet

Label TTM Value / Value Unit Change %
Cash and Cash Equivalents, at Carrying Value 6.8M USD -51%
Cash, Cash Equivalents, and Short-term Investments 6.8M USD -71.2%
Accounts Receivable, after Allowance for Credit Loss, Current 266K USD -66.2%
Other Assets, Current 0 USD -100%
Assets, Current 8.25M USD -67.1%
Property, Plant and Equipment, Net 2.98M USD -11%
Operating Lease, Right-of-Use Asset 376K USD -43.6%
Other Assets, Noncurrent 30K USD 0%
Assets 11.6M USD -60.1%
Accounts Payable, Current 796K USD -66.3%
Employee-related Liabilities, Current 0 USD -100%
Accrued Liabilities, Current 1.59M USD -44.4%
Liabilities, Current 2.77M USD -50.5%
Operating Lease, Liability, Noncurrent 62K USD -85%
Other Liabilities, Noncurrent 400K USD -16.7%
Liabilities 65.6M USD +2.57%
Accumulated Other Comprehensive Income (Loss), Net of Tax 5K USD
Retained Earnings (Accumulated Deficit) -374M USD -7.47%
Stockholders' Equity Attributable to Parent -54M USD -55.1%
Liabilities and Equity 11.6M USD -60.1%

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities -5.83M USD +25.7%
Net Cash Provided by (Used in) Financing Activities -553K USD -104%
Net Cash Provided by (Used in) Investing Activities -9K USD +84.2%
Common Stock, Shares Authorized 26.7M shares -86.7%
Common Stock, Shares, Issued 5.23M shares -93%
Common Stock, Par or Stated Value Per Share 0 USD/shares 0%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect -6.39M USD -199%
Deferred Tax Assets, Valuation Allowance 92.4M USD +9.93%
Operating Lease, Liability 703K USD -30.6%
Depreciation 85K USD +204%
Payments to Acquire Property, Plant, and Equipment 9K USD -84.2%
Property, Plant and Equipment, Gross 4.38M USD -0.86%
Operating Lease, Liability, Current 384K USD +2.95%
Deferred Tax Assets, Operating Loss Carryforwards 56M USD +6.39%
Preferred Stock, Shares Issued 0 shares
Preferred Stock, Shares Authorized 10M shares 0%
Unrecognized Tax Benefits 7.05M USD -6.26%
Additional Paid in Capital 320M USD +2.18%
Preferred Stock, Shares Outstanding 0 shares
Preferred Stock, Par or Stated Value Per Share 0 USD/shares 0%